OSTEOP
MCID: OST002
MIFTS: 74

Osteoporosis (OSTEOP)

Categories: Bone diseases, Fetal diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Osteoporosis

MalaCards integrated aliases for Osteoporosis:

Name: Osteoporosis 58 39 12 77 76 38 56 6 44 45 15 64 41 17 74
Postmenopausal Osteoporosis 76 30 6 17
Osteoporosis, Postmenopausal 58 74
Osteoporosis, Involutional 58 13
Bone Mineral Density Quantitative Trait Locus; Bmnd 58
Bone Mineral Density Variation Qtl, Osteoporosis 58
Bone Mineral Density, Quantitative Trait Locus 41
Bone Mineral Density Quantitative Trait Locus 58
Osteoporosis, Postmenopausal, Susceptibility 58
Osteoporosis, Susceptibility to 58
Osteoporosis Postmenopausal 56
Involutional Osteoporosis 76
Osteoporosis, Senile 74
Senile Osteoporosis 76
Osteop 76
Bmnd 58

Characteristics:

OMIM:

58
Inheritance:
autosomal dominant


HPO:

33
osteoporosis:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

Disease Ontology 12 DOID:11476
OMIM 58 166710
KEGG 38 H01593
ICD9CM 36 733.0 733.00
MeSH 45 D010024
NCIt 51 C3298
SNOMED-CT 69 64859006
ICD10 34 M80.0 M81.0
SNOMED-CT via HPO 70 263681008

Summaries for Osteoporosis

MedlinePlus : 44 Osteoporosis is a disease that thins and weakens the bones. Your bones become fragile and break easily, especially the bones in the hip, spine, and wrist. In the United States, millions of people either already have osteoporosis or are at high risk due to low bone mass. Anyone can develop osteoporosis, but it is more common in older women. Risk factors include Getting older Being small and thin Having a family history of osteoporosis Taking certain medicines Being a white or Asian woman Having low bone density Osteoporosis is a silent disease. You might not know you have it until you break a bone. A bone mineral density test is the best way to check your bone health. To keep bones strong, eat a diet rich in calcium and vitamin D, exercise, and do not smoke. If needed, medicines can also help. It is also important to try to avoid falling down. Falls are the number one cause of fractures in older adults. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

MalaCards based summary : Osteoporosis, also known as postmenopausal osteoporosis, is related to osteoporosis, juvenile and glucocorticoid-induced osteoporosis, and has symptoms including tremor, angina pectoris and back pain. An important gene associated with Osteoporosis is COL1A1 (Collagen Type I Alpha 1 Chain), and among its related pathways/superpathways are Osteoclast differentiation and Mineral absorption. The drugs Alendronate and Etidronic acid have been mentioned in the context of this disorder. Affiliated tissues include Bone and Bone, and related phenotypes are osteoporosis and hematopoietic system

Disease Ontology : 12 A bone resorption disease characterized by decreased density of normally mineralized bone which results in the thinning of bone tissue and decreased mechanical strength.

UniProtKB/Swiss-Prot : 76 Osteoporosis: A systemic skeletal disorder characterized by decreased bone mass and deterioration of bone microarchitecture without alteration in the composition of bone. The result is fragile bones and an increased risk of fractures, even after minimal trauma. Osteoporosis is a chronic condition of multifactorial etiology and is usually clinically silent until a fracture occurs.

PubMed Health : 64 About osteoporosis: Having weak bones that easily break is a sign of osteoporosis. It is normal for your bones to become less dense as you grow older, but osteoporosis speeds up this process. This condition can particularly lead to problems in older age because broken bones do not heal as easily in older people as they do in young people, and the consequences are more serious. In general, osteoporosis is more common in women, and they often develop it at a younger age.Getting older does not mean that you will automatically develop osteoporosis, but the risk does increase with age. People over the age of 70 are more likely to have low bone density. Plus, the risk of falling increases in old age, which then also makes fractures more likely.But there are several things you can do to protect and strengthen your bones – even if you are already older.

Wikipedia : 77 Osteoporosis is a disease in which bone weakening increases the risk of a broken bone. It is the most... more...

Description from OMIM: 166710

Related Diseases for Osteoporosis

Diseases in the Osteoporosis family:

Osteoporosis, Juvenile Juvenile Primary Osteoporosis
Lrp5-Related Primary Osteoporosis

Diseases related to Osteoporosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 669)
# Related Disease Score Top Affiliating Genes
1 osteoporosis, juvenile 35.4 BGLAP CALCA COL1A1 LRP5 WNT1
2 glucocorticoid-induced osteoporosis 34.9 BGLAP CALCA RUNX2 TNFRSF11B TNFSF11
3 bone mineral density quantitative trait locus 15 33.8 CALCR PDLIM4
4 bone disease 33.1 BGLAP CALCA COL1A1 DANCR LRP5 RUNX2
5 hyperparathyroidism 33.1 BGLAP CALCA TNFRSF11B VDR
6 rickets 33.0 BGLAP SLC34A1 VDR
7 osteopetrosis 32.9 LRP5 TNFRSF11A TNFSF11
8 osteogenesis imperfecta, type viii 32.3 COL1A1 COL1A2
9 bone resorption disease 32.1 BGLAP CALCA COL1A1 ESR1 LRP5 RUNX2
10 osteoporotic fracture 32.0 COL1A1 ESR1 TNFRSF11B
11 osteonecrosis 31.9 BGLAP RUNX2 TNFRSF11B TNFSF11
12 osteomalacia 31.7 BGLAP CALCA VDR
13 periodontitis 31.5 BGLAP RUNX2 TNFRSF11B TNFSF11
14 brittle bone disorder 31.4 BGLAP COL1A1 COL1A2
15 primary hyperparathyroidism 31.3 BGLAP CALCA VDR
16 periodontal disease 31.3 TNFRSF11A TNFRSF11B TNFSF11
17 chronic kidney failure 31.3 BGLAP CALCA TNFRSF11B VDR
18 paget's disease of bone 31.2 BGLAP CALCA TNFRSF11A TNFRSF11B TNFSF11
19 hyperostosis 31.0 COL1A1 LRP5 TNFRSF11B
20 otosclerosis 30.9 COL1A1 COL1A2 TNFRSF11B
21 bone inflammation disease 30.8 BGLAP TNFRSF11B TNFSF11
22 idiopathic hypercalciuria 30.8 BGLAP TNFSF11 VDR
23 endosteal hyperostosis, autosomal dominant 30.8 LRP5 TNFRSF11B TNFSF11
24 renal osteodystrophy 30.7 BGLAP CALCA TNFRSF11B VDR
25 hemophilic arthropathy 30.7 TNFRSF11A TNFRSF11B TNFSF11
26 periodontitis, chronic 30.7 TNFRSF11B TNFSF11
27 ankylosis 30.4 BGLAP RUNX2 TNFRSF11B
28 hyperphosphatemia 30.4 RUNX2 SLC34A1 VDR
29 protrusio acetabuli 30.4 ESR1 VDR
30 kummell's disease 30.3 TNFRSF11B TNFSF11
31 bone mineral density quantitative trait locus 1 12.7
32 osteoporosis-pseudoglioma syndrome 12.7
33 bone mineral density quantitative trait locus 17 12.7
34 bone mineral density quantitative trait locus 9 12.7
35 bone mineral density quantitative trait locus 10 12.7
36 bone mineral density quantitative trait locus 11 12.7
37 bone mineral density quantitative trait locus 13 12.7
38 bone mineral density quantitative trait locus 14 12.7
39 bone mineral density quantitative trait locus 4 12.6
40 bone mineral density quantitative trait locus 2 12.6
41 bone mineral density quantitative trait locus 5 12.6
42 bone mineral density quantitative trait locus 6 12.6
43 bone mineral density quantitative trait locus 7 12.6
44 nephrolithiasis/osteoporosis, hypophosphatemic, 1 12.5
45 juvenile primary osteoporosis 12.5
46 nephrolithiasis/osteoporosis, hypophosphatemic, 2 12.4
47 osteoporosis and oculocutaneous hypopigmentation syndrome 12.3
48 growth failure, microcephaly, mental retardation, cataracts, large joint contractures, osteoporosis, cortical dysplasia, and cerebellar atrophy 12.1
49 amino aciduria with mental deficiency, dwarfism, muscular dystrophy, osteoporosis, and acidosis 12.0
50 macroepiphyseal dysplasia with osteoporosis, wrinkled skin, and aged appearance 12.0

Comorbidity relations with Osteoporosis via Phenotypic Disease Network (PDN): (show top 50) (show all 85)


Active Peptic Ulcer Disease Acute Cor Pulmonale
Acute Cystitis Alzheimer Disease
Anxiety Aortic Atherosclerosis
Aortic Valve Disease 1 Asthma
Benign Essential Hypertension Bronchiectasis
Bronchitis Bronchopneumonia
Cerebral Atherosclerosis Cerebral Degeneration
Cerebrovascular Disease Chronic Myocardial Ischemia
Chronic Pulmonary Heart Disease Chylomicron Retention Disease
Conjunctivitis Conn's Syndrome
Cystitis Decubitus Ulcer
Deficiency Anemia Dermatomycosis
Dyskinesia of Esophagus Dysthymic Disorder
Esophagitis Femoral Vein Thrombophlebitis
Gastroesophageal Reflux Generalized Anxiety Disorder
Generalized Atherosclerosis Heart Disease
Hyperparathyroidism Hypertension, Essential
Hyperuricemia, Pulmonary Hypertension, Renal Failure, and Alkalosis Syndrome Hypothyroidism
Idiopathic Interstitial Pneumonia Inflammatory Bowel Disease 1
Intervertebral Disc Disease Intestinal Obstruction
Iron Deficiency Anemia Irritable Bowel Syndrome
Macular Degeneration, Age-Related, 1 Major Depressive Disorder
Marasmus Monoclonal Paraproteinemia
Neurogenic Bladder Nutritional Deficiency Disease
Opioid Addiction Oral Candidiasis

Graphical network of the top 20 diseases related to Osteoporosis:



Diseases related to Osteoporosis

Symptoms & Phenotypes for Osteoporosis

Human phenotypes related to Osteoporosis:

33
# Description HPO Frequency HPO Source Accession
1 osteoporosis 33 HP:0000939

Symptoms via clinical synopsis from OMIM:

58
Skel:
postmenopausal osteoporosis

Clinical features from OMIM:

166710

UMLS symptoms related to Osteoporosis:


tremor, angina pectoris, back pain, sciatica, equilibration disorder, muscle cramp, pelvic pain

MGI Mouse Phenotypes related to Osteoporosis:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.07 CALCR COL1A1 ESR1 LRP5 RUNX2 TNFRSF11A
2 immune system MP:0005387 10.02 CALCR COL1A1 ESR1 LRP5 RUNX2 TNFRSF11A
3 craniofacial MP:0005382 10.01 COL1A1 LRP5 RUNX2 TNFRSF11A TNFRSF11B TNFSF11
4 limbs/digits/tail MP:0005371 9.96 CALCR COL1A1 COL1A2 ESR1 LRP5 RUNX2
5 mortality/aging MP:0010768 9.93 CALCR COL1A1 COL1A2 ESR1 LRP5 RUNX2
6 muscle MP:0005369 9.56 COL1A1 COL1A2 ESR1 RUNX2 SLC34A1 TNFSF11
7 skeleton MP:0005390 9.4 CALCR COL1A1 COL1A2 ESR1 LRP5 RUNX2

Drugs & Therapeutics for Osteoporosis

PubMedHealth treatment related to Osteoporosis: 64

Even if someone already has osteoporosis, it is important for them to do regular exercise and get enough calcium and vitamin D. In Germany, statutory health insurances cover the cost of calcium or vitamin D supplements if a doctor has prescribed them.Osteoporosis can be treated with several drugs designed to slow bone loss and increase the production of new bone tissue. These include bisphosphonates and some hormonal or hormone-like medications. These kinds of drugs can have different types of side effects, though, and may not be suitable for everyone. They are only considered if someone has already broken a bone, or if their risk of bone fractures is high – for example, if their bone density is very low or if they have a combination of different risk factors, like low body weight, old age and a higher risk of falling.Hormone products, like those used to treat menopause symptoms, can also lower the risk of osteoporosis-related bone fractures when taken over the long term. But long-term hormone therapy during or after menopause increases the risk of cardiovascular diseases and breast cancer. For this reason it is only rarely recommended as treatment for osteoporosis. The pros and cons of this treatment should be carefully weighed.

Drugs for Osteoporosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 699)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Alendronate Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 66376-36-1, 121268-17-5 2088
2
Etidronic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7414-83-7, 2809-21-4 3305
3
Risedronate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 105462-24-6 5245
4
Benzocaine Approved, Investigational Phase 4,Phase 3,Not Applicable 1994-09-7, 94-09-7 2337
5
tannic acid Approved Phase 4,Phase 3,Not Applicable 1401-55-4
6
Tocopherol Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 1406-66-2 14986
7
Linagliptin Approved Phase 4,Phase 3 668270-12-0 10096344
8
Pioglitazone Approved, Investigational Phase 4,Phase 2 111025-46-8 4829
9
Teriparatide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 52232-67-4 16133850
10
Calcium Carbonate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 471-34-1
11
Denosumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 615258-40-7
12
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-28-2 5757
13
Progesterone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 57-83-0 5994
14
Medroxyprogesterone acetate Approved, Investigational Phase 4,Phase 3,Phase 1 71-58-9
15
Polyestradiol phosphate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 28014-46-2
16
Zoledronic Acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 118072-93-8 68740
17
Letrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 112809-51-5 3902
18
Emtricitabine Approved, Investigational Phase 4,Phase 2,Phase 3 143491-57-0 60877
19
Tenofovir Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 147127-20-6 464205
20
Parathyroid hormone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 9002-64-6
21
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 53-03-2 5865
22
Testosterone undecanoate Approved, Investigational Phase 4,Phase 2,Phase 3 5949-44-0
23
Methyltestosterone Approved Phase 4,Phase 2,Phase 3 58-18-4 6010
24
Testosterone enanthate Approved Phase 4,Phase 2,Phase 3 315-37-7 9416
25
Testosterone Approved, Experimental, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 58-22-0, 481-30-1 10204 6013
26
Bazedoxifene Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 198481-32-2
27
Racepinephrine Approved Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1 329-65-7 838
28
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1 51-43-4 5816
29
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 143 6006
30
rituximab Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 174722-31-7 10201696
31
Anastrozole Approved, Investigational Phase 4,Phase 3,Phase 2 120511-73-1 2187
32
Exemestane Approved, Investigational Phase 4,Phase 3,Not Applicable 107868-30-4 60198
33
Demeclocycline Approved Phase 4,Phase 2 127-33-3 5311063
34
Tetracycline Approved, Vet_approved Phase 4,Phase 2 60-54-8 5353990
35
Phylloquinone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 84-80-0
36 Menaquinone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1182-68-9
37
Tibolone Approved, Investigational Phase 4,Phase 3,Phase 2 5630-53-5
38
Atorvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 134523-00-5 60823
39
Esomeprazole Approved, Investigational Phase 4,Phase 1,Not Applicable 161796-78-7, 161973-10-0, 119141-88-7 9568614 4594
40
Acetaminophen Approved Phase 4,Phase 3,Phase 1,Not Applicable 103-90-2 1983
41
Sodium Citrate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 68-04-2
42
Cinacalcet Approved Phase 4,Phase 3,Not Applicable 226256-56-0 156419
43
Liraglutide Approved Phase 4,Early Phase 1 204656-20-2 44147092
44
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
45
Pamidronate Approved Phase 4,Phase 2,Phase 1,Not Applicable 40391-99-9 4674
46
Potassium Citrate Approved, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable
47
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
48
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
49
Angiotensin II Approved, Investigational Phase 4 11128-99-7, 68521-88-0, 4474-91-3 172198
50
Gliclazide Approved Phase 4 21187-98-4 3475

Interventional clinical trials:

(show top 50) (show all 1978)
# Name Status NCT ID Phase Drugs
1 Osteoporosis and Dental Implant Unknown status NCT00727493 Phase 4 alendronate once weekly 70mg;placebo
2 Efficacy and Safety of Brand Versus Generic Alendronate for Osteoporosis Treatment Unknown status NCT02371252 Phase 4 Generic alendronate
3 Efficacy and Safety Study of Risedronate, Cholecalciferol Combination Tablet in Patients With Osteoporosis Unknown status NCT01675297 Phase 4 Risedronate/Cholecalciferol combination;Risedronate
4 Determination of Vitamin D Dose to Maintain Sufficiency Amongst Indian and Malay Women in the Tropics Unknown status NCT02389179 Phase 4 Vitamin D3
5 A One-year Randomized Controlled Trial Evaluating the Impact of Pioglitazone Versus Linagliptin on Bone Turnover Markers Unknown status NCT02429232 Phase 4 Pioglitazone;Linagliptin
6 Clinical Comparison of Efficacy and Safety of Two Teriparatide Formulations: Osteofortil and Forteo Unknown status NCT01945788 Phase 4 Teriparatide (rDNA origin)
7 The Effect of Inactive and Active Vitamin D on Serum Sclerostin/dickkopf1 Levels Unknown status NCT01765010 Phase 4 Calcitriol;Alfacalcidol;Cholecalciferol;Placebo
8 Analgesic Effects of the Gastrolith, in Osteoporotic Patients Suffering From Recent Skeletal Pain Caused by Vertebral Fractures Unknown status NCT01482858 Phase 4
9 Study Evaluating Denosumab on Bone and Vascular Metabolism in Osteoporotic Chronic Kidney Disease Unknown status NCT02792413 Phase 4 Denosumab;NaCl (placebo)
10 Effects of Omega-3 Fatty Acids on Bone and Frailty Unknown status NCT00634686 Phase 4
11 Effect of Evogliptin on Bone Metabolism in Human Unknown status NCT02587975 Phase 4 Evogliptin
12 Short-term Functional Recovery Between Early- and Late Bisphosphonate Treatment Following Hemiarthroplasty Unknown status NCT02148848 Phase 4 Risedronate
13 Multi-centre Clinical Trial on Hormone Replacement Treatment in China Unknown status NCT01698164 Phase 4 estradiol plus MPA;Ximingting Tablet;estradiol plus progesterone
14 The Effect of Zoledronic Acid to Bone Fusion and Bone Metabolism of Patients With Lumbar Degenerative Disease After Lumbar Interbody Fusion Unknown status NCT01310465 Phase 4 zoledronic acid;sodium chloride
15 The Effect of Vitamin D Supplementation on Calcium Excretion in Thalassemia: a Dose Response Study Unknown status NCT01323608 Phase 4 Vitamin D3;Placebo
16 Multi-center Clinical Study of Guli Capsules in the Treatment of Knee Osteoarthritis Unknown status NCT02484508 Phase 4 Guli capsule;Kangguzengsheng capsule
17 Evaluation of Predictive Factors Regarding the Effectivity of Aromatase Inhibitor Therapy (PreFace) Unknown status NCT01908556 Phase 4 Letrozole
18 Alendronate for Vascular Calcification in Peritoneal Dialysis Patients? Unknown status NCT00299572 Phase 4 alendronate (Fosamax)
19 Alendronate for Prevention of AntiRetroviral Therapy-associated Bone Loss Unknown status NCT02322099 Phase 4 Alendronate;Placebo;Tenofovir disoproxil
20 Clinical Study of Raloxifene and Strontium Ranelate in Postmenopausal Osteoporosis Completed NCT01544894 Phase 4 Raloxifene;Strontium ranelate
21 A Study of Adherence to Once Monthly Ibandronate (Bonviva) in Women With Post-Menopausal Osteoporosis, Supported by a Patient Relationship Program (PRP) Completed NCT00545363 Phase 4 Ibandronate
22 Enhancing Osteoporosis Therapy: Can We Open the Anabolic Window? Completed NCT01166958 Phase 4 Teriparatide;Raloxifene
23 Teriparatide Treatment in Patients With Inherited Osteoporosis Completed NCT01360424 Phase 4 Teriparatide
24 Evaluation Of Missed Osteoporosis Diagnoses, And Preference Between Once Monthly Ibandronate And Once Weekly Alendronate Completed NCT00327990 Phase 4 Ibandronate;Alendronate
25 Effect of Full Length Parathyroid Hormone, PTH(1-84) or Strontium Ranelate on Bone Markers in Postmenopausal Women With Primary Osteoporosis (FP-006-IM) Completed NCT00479037 Phase 4 Full Length Parathyroid Hormone, PTH(1-84);Strontium Ranelate
26 Denosumab in Current Users of Bisphosphonates for Glucocorticoid-induced Osteoporosis Completed NCT01465568 Phase 4 Denosumab;bisphosphonates
27 ExBonAdAsia Study: A Study of Once Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis. Completed NCT00545090 Phase 4 ibandronate [Bonviva/Boniva]
28 Risedronate and Parathyroid Hormone to Reverse Osteoporosis Caused by Chronic Steroid Use Completed NCT00221299 Phase 4 Risedronate;Parathyroid Hormone
29 Danish Osteoporosis Prevention Study Completed NCT00252408 Phase 4 Hormone replacement therapy
30 A Study of Ibandronate (Boniva) to Evaluate Bone Turnover Markers in Women With Treatment-Naive Postmenopausal Osteoporosis Completed NCT02598934 Phase 4 Ibandronate
31 STEP: Study of Imaging Techniques (ImaTx and DXA) in Postmenopausal Women With OstEoporosis Using Preotact (FP-008-ES) Completed NCT00583518 Phase 4 Parathyroid hormone (PTH)
32 A Study of Ibandronate (Boniva) to Evaluate Satisfaction in Women With Post-Menopausal Osteoporosis or Osteopenia Completed NCT02604836 Phase 4 Ibandronate
33 Effects of Teriparatide or Denosumab on Bone in Postmenopausal Women With Osteoporosis Completed NCT01753856 Phase 4 Teriparatide;Denosumab;Demeclocycline;Tetracycline;Calcium Supplement;Vitamin D
34 HRT Versus Etidronate for Osteoporosis and Fractures in Asthmatics Receiving Glucocorticoids. Completed NCT00376662 Phase 4 Hormone Replacement Therapy and Etidronate
35 A Study of Teriparatide in Japanese Osteoporosis Patients Completed NCT01430104 Phase 4 Teriparatide;Aspara-CA 600 mg;Alfarol 1.0 µg
36 High Dosage Vitamin D and Osteoporosis Completed NCT00491920 Phase 4 cholecalciferol (Vitamin D3);placebo
37 A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis Completed NCT02598440 Phase 4 Alendronate;Ibandronate
38 A Study of Prevention and Treatment of Postmenopausal Osteoporosis in Chinese Women Completed NCT00860964 Phase 4 Placebo;estradiol valerate
39 Prevention of Osteoporosis in Breast Cancer Survivors Completed NCT00567606 Phase 4
40 PRIOR Study - A Study of Ibandronate (Boniva) in Postmenopausal Women With Osteoporosis or Osteopenia Completed NCT02598453 Phase 4 Ibandronate
41 Study To Investigate Patient Preference On Dosing In Ibandronate And Risedronate In Korean Women With Postmenopausal Osteoporosis Completed NCT00405392 Phase 4 Ibandronate (SB743830HD)
42 A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Previously Treated With Bonviva Completed NCT00081653 Phase 4 ibandronate [Bonviva/Boniva];ibandronate [Bonviva/Boniva]
43 Evaluation of the Effects of Teriparatide on Skeleton Images in Postmenopausal Women With Osteoporosis Completed NCT00259298 Phase 4 teriparatide
44 A Study of Once Monthly Bonviva (Ibandronate) in Prevention of Glucocorticoid-Induced Osteoporosis. Completed NCT00545051 Phase 4 Placebo;ibandronate
45 2-Year Therapy With Teriparatide vs 1-yr Therapy Followed by 1-Year of Raloxifene or Calcium/Vit D in Severe Postmenopausal Osteoporosis Completed NCT00191425 Phase 4 Teriparatide;Raloxifene
46 BEATRIS Study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women With Post-Menopausal Osteoporosis Completed NCT00545909 Phase 4 ibandronate [Bonviva/Boniva];ibandronate [Bonviva/Boniva]
47 SUMMIT Study: A Study of Persistence to Bonviva (Ibandronate) Once Monthly in Women With Post-Menopausal Osteoporosis. Completed NCT00545480 Phase 4 ibandronate [Bonviva/Boniva];ibandronate [Bonviva/Boniva]
48 A Study To Assess the Quality and Strength of Bone in Women Participants With Osteoporosis Taking Oral Ibandronate Versus Placebo Completed NCT00148915 Phase 4 ibandronate;Placebo
49 A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Who Have Received Previous Bonviva Treatment Completed NCT00551174 Phase 4 ibandronate [Bonviva/Boniva];ibandronate [Bonviva/Boniva]
50 A Study of Bone Turnover Markers in Post-Menopausal Women With Osteoporosis Treated With Monthly Boniva (Ibandronate) Completed NCT00303485 Phase 4 Placebo;Vitamin D and calcium supplementation;ibandronate [Bonviva/Boniva]

Search NIH Clinical Center for Osteoporosis

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Osteoporosis cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Osteoporosis:
PREOB, autologous osteoblasts for bone disorders

Cochrane evidence based reviews: osteoporosis

Genetic Tests for Osteoporosis

Genetic tests related to Osteoporosis:

# Genetic test Affiliating Genes
1 Postmenopausal Osteoporosis 30 CALCR COL1A1 COL1A2 LRP5 PDLIM4 VDR

Anatomical Context for Osteoporosis

MalaCards organs/tissues related to Osteoporosis:

42
Bone, Testes, Kidney, Spinal Cord, Bone Marrow, Skin, Thyroid
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Osteoporosis:
# Tissue Anatomical CompartmentCell Relevance
1 Bone Bone Marrow Mononucleated Osteoclasts Affected by disease
2 Bone Bone Marrow Multinucleated Osteoclasts Affected by disease
3 Blood Hematopoietic Bone Marrow Osteoclast Precursor Cells Affected by disease

Publications for Osteoporosis

Articles related to Osteoporosis:

(show top 50) (show all 8621)
# Title Authors Year
1
Bmi1 Overexpression in Mesenchymal Stem Cells Exerts Anti-Aging and Anti-Osteoporosis Effects by Inactivating p16/p19 Signaling And Inhibiting Oxidative Stress. ( 30895687 )
2019
2
Hydroxytyrosol protects from aging process via AMPK and autophagy; a review of its effects on cancer, metabolic syndrome, osteoporosis, immune-mediated and neurodegenerative diseases. ( 30853597 )
2019
3
Osteoporosis, Childhood Bullying, Rheumatoid Arthritis, Diabetes Counseling, Inhaled Steroids. ( 30874411 )
2019
4
Correlation between systemic osteoporosis and local bone erosion with rheumatoid arthritis patients in Chinese population. ( 30847477 )
2019
5
Calcium and vitamin D supplementation with 3-year denosumab treatment is beneficial to enhance bone mineral density in postmenopausal patients with osteoporosis and rheumatoid arthritis. ( 30588001 )
2019
6
Association of Bone Metastasis With Early-Stage Breast Cancer in Women With and Without Precancer Osteoporosis According to Osteoporosis Therapy Status. ( 30848812 )
2019
7
Colorectal Cancer, Osteoporosis, Knee Osteoarthritis, Suspected Dementia, Pacifier Use. ( 30990293 )
2019
8
Cognition and Vitamin D in Older African-American Women- Physical performance and Osteoporosis prevention with vitamin D in older African Americans Trial and Dementia. ( 30359476 )
2019
9
Osteoporosis and vertebral fracture are associated with deterioration of activities of daily living and quality of life in patients with type 2 diabetes mellitus. ( 30191456 )
2019
10
Retrospective longitudinal study of osteoporosis in adults with recessive dystrophic epidermolysis bullosa. ( 30656009 )
2019
11
Increased Risk of Osteoporosis in Gastric Cancer Survivors Compared to General Population Control: A Study with Representative Korean Population. ( 29986577 )
2019
12
Preventative effects of metformin on glucocorticoid-induced osteoporosis in rats. ( 30706148 )
2019
13
Glucocorticoid-induced osteoporosis preventive care in rheumatology patients. ( 30723883 )
2019
14
Glucocorticoid-induced osteoporosis: 2019 concise clinical review. ( 30805679 )
2019
15
Denosumab vs risedronate in glucocorticoid-induced osteoporosis: final results of a 24-month randomized, double-blind, double-dummy trial. ( 30816640 )
2019
16
Z-Guggulsterone attenuates glucocorticoid-induced osteoporosis through activation of Nrf2/HO-1 signaling. ( 30905781 )
2019
17
Glucocorticoid-Induced Osteoporosis. ( 30943350 )
2019
18
Glucocorticoid-Induced Osteoporosis. Reply. ( 30943351 )
2019
19
Liraglutide increases bone formation and inhibits bone resorption in rats with glucocorticoid-induced osteoporosis. ( 30955181 )
2019
20
Glucocorticoid-induced osteoporosis update. ( 31045947 )
2019
21
Glucocorticoid induced osteoporosis. ( 31094232 )
2019
22
Osteoprotective Effect of Cimiracemate in Glucocorticoid-Induced Osteoporosis by Osteoprotegerin/Receptor Activator of Nuclear Factor κ B/Receptor Activator of Nuclear Factor Kappa-Β Ligand Signaling. ( 30695776 )
2019
23
Metabolomics profiling provides valuable insights into the underlying mechanisms of Morinda officinalis on protecting glucocorticoid-induced osteoporosis. ( 30690247 )
2019
24
Glucocorticoid-Induced Osteoporosis: New Insights into the Pathophysiology and Treatments. ( 30685820 )
2019
25
Metabolomics Profiling Reveals Rehmanniae Radix Preparata Extract Protects against Glucocorticoid-Induced Osteoporosis Mainly via Intervening Steroid Hormone Biosynthesis. ( 30641909 )
2019
26
Cost-effectiveness of implementing guidelines for the treatment of glucocorticoid-induced osteoporosis in Japan. ( 30610244 )
2019
27
The prevention of glucocorticoid-induced osteoporosis in patients with immune thrombocytopenia receiving steroids: a British Society for Haematology Good Practice Paper. ( 30609018 )
2019
28
Osteoblast autophagy in glucocorticoid-induced osteoporosis. ( 30417506 )
2019
29
Luteolin attenuates glucocorticoid-induced osteoporosis by regulating ERK/Lrp-5/GSK-3β signaling pathway in vivo and in vitro. ( 30192012 )
2019
30
Denosumab is effective toward glucocorticoid-induced osteoporosis patients complicated with rheumatic diseases regardless of prior anti-osteoporotic drugs. ( 30187273 )
2019
31
Glucocorticoid-Induced Osteoporosis: Management Challenges in Older Patients. ( 29941355 )
2019
32
Prevention of Glucocorticoid-Induced Osteoporosis: Clinical audit to evaluate the implementation of National Osteoporosis Guideline Group 2017 guidelines in a primary care setting. ( 29729949 )
2019
33
Pro-inflammatory Cytokines: Cellular and Molecular Drug Targets for Glucocorticoid-induced-osteoporosis via Osteocyte. ( 29618305 )
2019
34
Necrotizing fasciitis as a complication of osteonecrosis of the jaw related to oral bisphosphonate application in a patient with osteoporosis: a case report. ( 30288621 )
2019
35
Atopic dermatitis is associated with osteoporosis and osteopenia in older adults. ( 29800580 )
2019
36
Severe hypocalcemia following denosumab treatment in a patient with secondary osteoporosis associated with primary sclerosing cholangitis. ( 30713246 )
2019
37
Adults With Cerebral Palsy Have Higher Prevalence of Fracture Compared With Adults Without Cerebral Palsy Independent of Osteoporosis and Cardiometabolic Diseases. ( 30730595 )
2019
38
Incidence of osteoarthritis, osteoporosis and inflammatory musculoskeletal diseases in adults with cerebral palsy: A population-based cohort study. ( 31075418 )
2019
39
Association Between Cataract and Risks of Osteoporosis and Fracture: A Nationwide Cohort Study. ( 30281143 )
2019
40
Oxygen desaturation during the 6-min walk test as a risk for osteoporosis in non-cystic fibrosis bronchiectasis. ( 30717716 )
2019
41
Conventional synthetic disease-modifying antirheumatic drugs and bone mineral density in rheumatoid arthritis patients with osteoporosis: possible beneficial effect of leflunomide. ( 30767868 )
2019
42
Evaluation of the implementation of guidelines on the treatment of osteoporosis in patients with rheumatoid arthritis. ( 30877214 )
2019
43
Opportunistic screening for osteoporosis using thoraco-abdomino-pelvic CT-scan assessing the vertebral density in rheumatoid arthritis patients. ( 30868182 )
2019
44
Correction to: Bisphosphonate therapy for spinal osteoporosis in Hajdu-Cheney syndrome - new data and literature review. ( 31077240 )
2019
45
The association between hepatitis and osteoporosis: a nested case-control study using a national sample cohort. ( 30852676 )
2019
46
Antiviral therapy and the development of osteopenia/osteoporosis among Asians with chronic hepatitis B. ( 30776311 )
2019
47
Herpes zoster and the risks of osteoporosis and fracture: a nationwide cohort study. ( 30460416 )
2019
48
Predictors of nephrolithiasis, osteoporosis and mortality in primary hyperparathyroidism. ( 30916764 )
2019
49
Exercise Alleviates Osteoporosis in Rats with Mild Chronic Kidney Disease by Decreasing Sclerostin Production. ( 31027235 )
2019
50
Correlation of the severity of chronic kidney disease with serum inflammation, osteoporosis and vitamin D deficiency. ( 30651805 )
2019

Variations for Osteoporosis

UniProtKB/Swiss-Prot genetic disease variations for Osteoporosis:

76
# Symbol AA change Variation ID SNP ID
1 WNT1 p.Cys218Gly VAR_069629 rs397514702
2 WNT1 p.Arg235Trp VAR_069630 rs387907359

ClinVar genetic disease variations for Osteoporosis:

6 (show top 50) (show all 57)
# Gene Variation Type Significance SNP ID Assembly Location
1 COL1A2 NM_000089.3(COL1A2): c.1981G> A (p.Gly661Ser) single nucleotide variant Pathogenic rs72658152 GRCh37 Chromosome 7, 94047820: 94047820
2 COL1A2 NM_000089.3(COL1A2): c.1981G> A (p.Gly661Ser) single nucleotide variant Pathogenic rs72658152 GRCh38 Chromosome 7, 94418508: 94418508
3 COL1A1 NM_000088.3(COL1A1): c.994G> A (p.Gly332Arg) single nucleotide variant Pathogenic rs72645357 GRCh37 Chromosome 17, 48273524: 48273524
4 COL1A1 NM_000088.3(COL1A1): c.994G> A (p.Gly332Arg) single nucleotide variant Pathogenic rs72645357 GRCh38 Chromosome 17, 50196163: 50196163
5 COL1A1 NM_000088.3(COL1A1): c.3040C> T (p.Arg1014Cys) single nucleotide variant Pathogenic rs72653170 GRCh37 Chromosome 17, 48266269: 48266269
6 COL1A1 NM_000088.3(COL1A1): c.3040C> T (p.Arg1014Cys) single nucleotide variant Pathogenic rs72653170 GRCh38 Chromosome 17, 50188908: 50188908
7 LRP5 NM_002335.3(LRP5): c.4000+9C> T single nucleotide variant Conflicting interpretations of pathogenicity rs148685646 GRCh37 Chromosome 11, 68201315: 68201315
8 LRP5 NM_002335.3(LRP5): c.4000+9C> T single nucleotide variant Conflicting interpretations of pathogenicity rs148685646 GRCh38 Chromosome 11, 68433847: 68433847
9 LRP5 NM_002335.3(LRP5): c.4635C> T (p.Thr1545=) single nucleotide variant Likely benign rs145406397 GRCh37 Chromosome 11, 68216325: 68216325
10 LRP5 NM_002335.3(LRP5): c.4635C> T (p.Thr1545=) single nucleotide variant Likely benign rs145406397 GRCh38 Chromosome 11, 68448857: 68448857
11 LRP5 NM_002335.2(LRP5): c.3107G> A (p.Arg1036Gln) single nucleotide variant Conflicting interpretations of pathogenicity rs61889560 GRCh37 Chromosome 11, 68191036: 68191036
12 LRP5 NM_002335.2(LRP5): c.3107G> A (p.Arg1036Gln) single nucleotide variant Conflicting interpretations of pathogenicity rs61889560 GRCh38 Chromosome 11, 68423568: 68423568
13 COL1A2 NM_000089.3(COL1A2): c.3034G> A (p.Gly1012Ser) single nucleotide variant Pathogenic/Likely pathogenic rs72659319 GRCh38 Chromosome 7, 94426459: 94426459
14 COL1A2 NM_000089.3(COL1A2): c.3034G> A (p.Gly1012Ser) single nucleotide variant Pathogenic/Likely pathogenic rs72659319 GRCh37 Chromosome 7, 94055771: 94055771
15 46;XY;t(1;9;5)(compleX)dn Translocation Likely pathogenic
16 COL1A2 NM_000089.3(COL1A2): c.3047C> A (p.Pro1016His) single nucleotide variant Uncertain significance rs377278762 GRCh37 Chromosome 7, 94055784: 94055784
17 COL1A2 NM_000089.3(COL1A2): c.3047C> A (p.Pro1016His) single nucleotide variant Uncertain significance rs377278762 GRCh38 Chromosome 7, 94426472: 94426472
18 COL1A1 NM_000088.3(COL1A1): c.2089C> T (p.Arg697Ter) single nucleotide variant Pathogenic rs72651642 GRCh37 Chromosome 17, 48269187: 48269187
19 COL1A1 NM_000088.3(COL1A1): c.2089C> T (p.Arg697Ter) single nucleotide variant Pathogenic rs72651642 GRCh38 Chromosome 17, 50191826: 50191826
20 COL1A1